

# July 2025 Content Release Notes

July 31, 2025

## Contents

Clinical Profile Documentation .....	2
Additions .....	2
Lab Analytes & Panels .....	2
Precision Medicine Updates .....	2
Additions and Updates .....	2
Medications .....	4
Additions .....	4
Updates .....	5
Regimen Library .....	7
Additions .....	7
Updates .....	8
Renames .....	9
Removals .....	9
Billing & HCPCS Codes .....	10
Updates .....	10
NDC – HCPCS Crosswalk .....	11

## Clinical Profile Documentation

### Additions

The **Problems > Add Details** area is updated with applicable documentation points for the following diagnoses.

**Curbside Connect with Dr. Yardley for HR+, HER2-, and Triple Negative patients** is now available for **Breast Cancer**.

## Lab Analytes & Panels

### Precision Medicine Updates

The **Guardant360 TissueNext PD-L1 panel** has been retired and replaced with the new **Guardant360 Tissue PD-L1 panel**. Additionally, the **Guardant360 TissueNext panel** has been renamed to the **Guardant360 Tissue panel**.

The **FoundationOne Heme panel** and the **Guardant Reveal Panel** are now available in PMO through the PMO drawer.

### Additions and Updates

- ANTI GM-1, IgG panel
- ATM gene panel
- BARD1 gene panel
- BRIP1 gene panel
- C. difficile detection
- CDKN2A gene panel
- Clobazam, serum, ng/mL
- Compass with clonoSEQ - blood panel
- Compass with clonoSEQ - bone marrow panel
- Compass without clonoSEQ - blood panel
- Compass without clonoSEQ - bone marrow panel
- Comprehensive hemeSeq panel
- CSF AGNA-1
- CSF amphiphysin antibody

- CSF ANNA type 3
- CSF Anti-Hu Ab
- CSF Anti-Ri Ab
- CSF CASPR2 antibody, IFA
- CSF CRMP-5 IgG
- CSF LGI1 antibody, IFA
- CSF paraneoplastic Ab interpretation
- CSF paraneoplastic Ab profile
- CSF PCA type-1 (Anti-Yo) Ab
- CSF purkinje cell cyto Ab type 2
- CSF purkinje cell cyto Ab type Tr
- Decipher (Veracyte)
- Desmethylclobazam, serum, ng/mL
- Est average glucose (eAG), mg/dL
- F12 gene panel
- F2 gene panel
- F5;F2 gene panel
- FoundationOne Ventana MET (SP44) panel
- GM-1 IgG autoantibodies interpretation
- GM-1 IgG autoantibodies, %
- Guardant360 Tissue PD-L1 panel
- Hgb A1C, %
- Hgb electrophoresis pathologist
- Invitae chromosomal microarray analysis (CMA) panel
- Invitae epilepsy panel
- Invitae hyper IgE syndrome panel
- Invitae iron related disorders including anemia panel + Invitae comprehensive porphyrias panel
- KRT5 gene panel
- Lanreotide panel
- MUTYH gene panel
- MXD#,  $\times 10^3/\mu\text{L}$
- Parvovirus B19 DNA quantitative by PCR panel
- PDE10A Ab IFA, S
- SDHB gene panel
- STK11 gene panel
- Trypanosoma cruzi Ab, confirmation
- Varicella zoster, IgG, S/CO

# Medications

## Additions

- Acasunlimab invest (GEN1046 invest IV)
- Anitocabtagene Autoleucel invest (KITE-772 invest IV)
- AVZO-1418 invest IV
- BL-M11D1 invest IV
- BMS-986507 invest IV
- Compound Benzocaine-Lidocaine-Tetracaine Topical 20 %-10 %-10 %
- Compound Budesonide Nasal Irrigation
- DR-0202 invest IV
- ENV-501 invest IV
- Fiber Supplement (inulin) Oral
- GEN1046 invest IV
- Givinostat invest Oral
- IBI3009 invest IV
- Igrelimogene Litadenorepvec invest (TILT-123 invest IV)
- Izalontamab Brengitecan invest (BMS-986507 invest IV)
- JZP815 invest Oral
- KITE-772 invest IV
- KQB168 invest Oral
- Prevagen Oral
- TILT-123 invest IV
- TOS-358 invest Oral
- TPN Electrolytes IV

## Updates

Medications	Updates
<b>BG-68501 invest Oral</b>	New <b>Form</b> available: <ul style="list-style-type: none"> <li>100 mg tablet</li> </ul>
<b>Gallium 68Ga Gozetotide or 68Ga Ga-PSMA-11 invest IV</b>	Remove <b>Instructions</b> : <ul style="list-style-type: none"> <li>Administered doses should not be lower than 111 MBq or higher than 180 MBq</li> </ul> New <b>Instructions</b> available: <ul style="list-style-type: none"> <li>Administered doses should not be lower than 111 MBq or higher than 259 MBq</li> <li>Administered doses should not be lower than 3 mCi or higher than 7 mCi</li> </ul>
<b>HER3-DXd invest IV</b>	New <b>Alias</b> available: <ul style="list-style-type: none"> <li>Patritumab Deruxtecan (MK-1022) invest</li> </ul>
<b>NVL-655 invest Oral</b>	New <b>Alias</b> available: <ul style="list-style-type: none"> <li>Neladalkib invest</li> </ul>
<b>Rituximab IV</b>	Remove <b>Maximum Single Dose</b> : <ul style="list-style-type: none"> <li>1,250 mg</li> </ul> New <b>Maximum Single Dose</b> available: <ul style="list-style-type: none"> <li>1,875 mg</li> </ul>
<b>Rituximab-abbs IV</b>	Remove <b>Maximum Single Dose</b> : <ul style="list-style-type: none"> <li>1,250 mg</li> </ul> New <b>Maximum Single Dose</b> available: <ul style="list-style-type: none"> <li>1,875 mg</li> </ul>
<b>Rituximab-arrx IV</b>	New <b>Maximum Single Dose</b> available: <ul style="list-style-type: none"> <li>1,875 mg</li> </ul>

Medications	Updates
Rituximab-pvvr IV	Remove <b>Maximum Single Dose</b> : <ul style="list-style-type: none"> <li>• 1,250 mg</li> </ul> New <b>Maximum Single Dose</b> available: <ul style="list-style-type: none"> <li>• 1,875 mg</li> </ul>
Talectrectinib invest Oral	New <b>Name</b> available: <ul style="list-style-type: none"> <li>• AB-106/DS-6051b invest Oral</li> </ul> New <b>Form</b> available: <ul style="list-style-type: none"> <li>• 100 mg capsule</li> </ul> New <b>Alias</b> available: <ul style="list-style-type: none"> <li>• Talectrectinib invest</li> </ul>
Zelenectide pevedotin invest (BT8009 invest IV)	New <b>Quick SIG Pick</b> available: <ul style="list-style-type: none"> <li>• 3 mg/m2 intravenously As Directed</li> <li>• 4.2 mg/m2 intravenously As Directed</li> <li>• 6 mg/m2 intravenously As Directed</li> </ul>

# Regimen Library

## Additions

Regimen Name	Diagnosis
<b>Daratumumab IV + Bortezomib D1,8,15 + Dexamethasone Q21D (Part 1 of 2)</b>	Multiple Myeloma (MM)
<b>Daratumumab IV + Lenalidomide + Bortezomib D1,8,15 + Dexamethasone (RVD) Q21D (Part 1 of 2)</b>	Multiple Myeloma (MM)
<b>Daratumumab IV + Lenalidomide + Bortezomib D1,8,15 + Dexamethasone (RVD) Q21D (Part 1 of 2: C1 Split Dosing)</b>	Multiple Myeloma (MM)
<b>Daratumumab SQ + Bortezomib D1,8,15 + Dexamethasone Q21D (Part 1 of 2)</b>	Multiple Myeloma (MM)
<b>Daratumumab SQ + Lenalidomide + Bortezomib D1,8,15 + Dexamethasone (RVD) Q21D (Part 1 of 2)</b>	Multiple Myeloma (MM)
<b>Daratumumab SQ + Lenalidomide + Bortezomib D1,8,15,22 + Dexamethasone (RVD) (PERSEUS) Q28D (Part 1 of 2)</b>	Multiple Myeloma (MM)
<b>Nivolumab (1 mg/kg) + Ipilimumab (3 mg/kg) C1 D1,22,43,64 (Q21D) fb Nivolumab SQ C2+ D1,29,57 (Q28D) Maintenance Q84D</b>	Hepatocellular Carcinoma (HCC); Melanoma, Skin; Melanoma, Uvea, Ciliary Body/Choroid

Regimen Name	Diagnosis
<b>Pomalidomide D1-21 + Bortezomib D1,8,15,22 + Dexamethasone Q28D</b>	Multiple Myeloma (MM)
<b>Taletrectinib Q30D</b>	Lung Cancer, Non-small Cell (NSCLC)
<b>Tislelizumab-jsgr Q14D</b>	Anal Cancer (Parent), Colon Cancer, Esophageal Cancer (Parent), Hepatocellular Carcinoma (HCC), Rectal Cancer
<b>Tislelizumab-jsgr Q28D</b>	Anal Cancer (Parent), Colon Cancer, Esophageal Cancer (Parent), Hepatocellular Carcinoma (HCC), Rectal Cancer

## Updates

The **Collaborative Care Committee** recently voted to **pre-check magnesium IV pre-hydration** in all **cisplatin-containing regimens**. This update will begin in July and be completed with the August content release.

Regimens for the following diagnoses have been updated based on the Collaborative Care Committee voting. Changes include but are not limited to reference update, drug infusion instruction updates, renaming of regimens, premedication template updates and number of cycles.

- All Problems
- Anal Cancer (Parent)
- Bile Duct Cancer (Parent)
- Bladder Cancer
- Breast Cancer
- Cervical Cancer
- Colon Cancer
- Esophageal Cancer (Parent)
- Fallopian Tube Cancer
- Gallbladder Cancer
- Gastric Cancer
- Head and Neck Cancer (Parent)
- Hepatocellular Carcinoma (HCC)
- Leukemia, Chronic Lymphocytic (CLL)

- Lung Cancer, Non-small Cell (NSCLC)
- Lung Cancer, Small Cell (SCLC)
- Lymphoma, Hodgkin (HL)
- Lymphoma, Non-Hodgkin (NHL) (Parent)
- Melanoma, Skin
- Melanoma, Uvea, Ciliary Body/Choroid
- Multiple Myeloma (MM)
- Ovarian and Primary Peritoneal Cancer
- Pancreatic Cancer
- Rectal Cancer
- Renal Pelvis and Ureter Cancer
- Testicular Cancer (Parent)
- Urethral Cancer
- Uterine Cancer (Parent)
- Vulva Cancer

## Renames

Previous Name	New Name
<b>Denosumab (Prolia) Q6M</b>	Denosumab (60 mg) Q6M
<b>Nivolumab (1 mg/kg) + Ipilimumab (3 mg/kg) Q21D</b>	Nivolumab (1 mg/kg) + Ipilimumab (3 mg/kg) C1 D1,22,43,64 (Q21D) fb Nivolumab IV C2+ D1,29,57 (Q28D) Maintenance Q84D

## Removals

Regimen Name	Diagnosis
<b>Influenza Vaccines 2024-2025</b>	All Problems

## Billing & HCPCS Codes

### Updates

Medication	HCPCS Codes
<b>Albumin, iodinated I-131 IV</b>	A9524 per: <ul style="list-style-type: none"> <li>• 5 mci</li> <li>• 5 microCi</li> </ul>
<b>Atidarsagene autotemcel IV</b>	J3391 per 6.6 x 10e6 CD34+ cells
<b>Denosumab-bmwo Subcutaneous (120 mg/1.7 mL - Osenvelt)</b>	J3590 per 120 mg
<b>Denosumab-bmwo Subcutaneous (60 mg/mL - Stoboclo)</b>	J3590 per 60 mg
<b>Denosumab-bnht Subcutaneous (120 mg/1.7 mL - Bomynta)</b>	J3590 per 120 mg
<b>Denosumab-bnht Subcutaneous (60 mg/mL - Conexence)</b>	J3590 per 60 mg
<b>Foscarbidopa-foslevodopa Continuous Subcutaneous Infusion</b>	J7356 per: <ul style="list-style-type: none"> <li>• 0.25 mg</li> <li>• 0.02083 mL</li> </ul>
<b>Foscarbidopa-foslevodopa Subcutaneous</b>	J7356 per: <ul style="list-style-type: none"> <li>• 0.25 mg</li> <li>• 0.02083 mL</li> </ul>
<b>Garadacimab-gxii Subcutaneous Auto-Injector</b>	J3590 per 200 mg
<b>Linvoseltamab-gcpt IV</b>	J9999 per 200 mg

Medication	HCPCS Codes
Meloxicam IV	J3490 per 30 mg
Nipocalimab-aahu IV	J3590 per 1200 mg
Nivolumab-hyaluronidase-nvhy Subcutaneous 600 mg-10,000 unit/5 mL	J9289 per: <ul style="list-style-type: none"> <li>• 2 mg</li> <li>• 0.016667 mL</li> </ul>
Ustekinumab-srlf IV	Q5098 per 1 mg
Ustekinumab-srlf Subcutaneous	Q5098 per 1 mg

## NDC – HCPCS Crosswalk

### Additions

Medication (Brand)	HCPCS Codes	NDC
Ustekinumab-srlf IV (Imdulsa)	Q5098 per 1 mg	<ul style="list-style-type: none"> <li>• 51407093111</li> <li>• 69448001926</li> </ul>
Ustekinumab-srlf Subcutaneous (Imdulsa)	Q5098 per 1 mg	<ul style="list-style-type: none"> <li>• 51407092911</li> <li>• 51407093011</li> <li>• 69448001763</li> <li>• 69448001863</li> </ul>